These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 3114665

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Desenkephalin-gamma-endorphin is an antagonist of the hyperactivity response induced by infusion of dopamine into the nucleus accumbens of rat and ventral striatum of marmoset.
    Costall B, Domeney AM, Naylor RJ.
    Neuropharmacology; 1989 Nov; 28(11):1223-9. PubMed ID: 2574424
    [Abstract] [Full Text] [Related]

  • 3. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain.
    Costall B, Domeney AM, Naylor RJ, Tyers MB.
    Br J Pharmacol; 1987 Dec; 92(4):881-94. PubMed ID: 2962686
    [Abstract] [Full Text] [Related]

  • 4. The continuity of dopamine receptor antagonism can dictate the long-term behavioural consequences of a mesolimbic infusion of dopamine.
    Costall B, Domeney AM, Naylor RJ.
    Neuropharmacology; 1985 Mar; 24(3):193-7. PubMed ID: 3990920
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the behavioural consequences of chronic stimulation of dopamine receptors in the nucleus accumbens of rat brain effected by a continuous infusion or by single daily injections.
    Costall B, Domeney AM, Naylor RJ.
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(1):27-33. PubMed ID: 6633677
    [Abstract] [Full Text] [Related]

  • 6. Behavioural consequences of the infusion of dopamine into the nucleus accumbens of the common marmoset (Callithrix jacchus).
    Barnes NJ, Costall B, Domeney AM, Naylor RJ.
    Neuropharmacology; 1987 Sep; 26(9):1327-35. PubMed ID: 2890118
    [Abstract] [Full Text] [Related]

  • 7. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats.
    Hall MD, Cooper DR, Fleminger S, Rupniak NM, Jenner P, Marsden CD.
    Neuropharmacology; 1984 May; 23(5):545-53. PubMed ID: 6539859
    [Abstract] [Full Text] [Related]

  • 8. Actions of ORG 5222 as a novel psychotropic agent.
    Costall B, Domeney AM, Kelly ME, Naylor RJ, Tomkins DM.
    Pharmacol Biochem Behav; 1990 Mar; 35(3):607-15. PubMed ID: 2111028
    [Abstract] [Full Text] [Related]

  • 9. Behavioural and biochemical changes following chronic administration of L-dopa to rats.
    Pycock C, Dawbarn D, O'Shaughnessy C.
    Eur J Pharmacol; 1982 Apr 23; 79(3-4):201-15. PubMed ID: 7201400
    [Abstract] [Full Text] [Related]

  • 10. Long-term consequences of antagonism by neuroleptics of behavioural events occurring during mesolimbic dopamine infusion.
    Costall B, Domeney AM, Naylor RJ.
    Neuropharmacology; 1984 Mar 23; 23(3):287-94. PubMed ID: 6145111
    [Abstract] [Full Text] [Related]

  • 11. Locomotor hyperactivity caused by dopamine infusion into the nucleus accumbens of rat brain: specificity of action.
    Costall B, Domeney AM, Naylor RJ.
    Psychopharmacology (Berl); 1984 Mar 23; 82(3):174-80. PubMed ID: 6144126
    [Abstract] [Full Text] [Related]

  • 12. Role of dopaminergic and GABAergic mechanisms in discrete brain areas in phencyclidine-induced locomotor stimulation and turning behavior.
    Yamaguchi K, Nabeshima T, Kameyama T.
    J Pharmacobiodyn; 1986 Dec 23; 9(12):975-86. PubMed ID: 3033192
    [Abstract] [Full Text] [Related]

  • 13. MPTP-induced hypoactivity in mice: reversal by L-dopa.
    Fredriksson A, Plaznik A, Sundström E, Jonsson G, Archer T.
    Pharmacol Toxicol; 1990 Oct 23; 67(4):295-301. PubMed ID: 2077520
    [Abstract] [Full Text] [Related]

  • 14. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J, Rogóz Z, Skuza G, Kołodziejczyk K.
    Eur J Pharmacol; 1997 Apr 11; 324(1):31-7. PubMed ID: 9137910
    [Abstract] [Full Text] [Related]

  • 15. Subacute L-DOPA in mice: biochemical and behavioural effects.
    Jenkins O, Bailey R, Crisp E, Jackson DM.
    Psychopharmacology (Berl); 1980 Apr 11; 68(1):77-83. PubMed ID: 6771801
    [Abstract] [Full Text] [Related]

  • 16. Lithium and bupropion antagonise the phasic changes in locomotor activity caused by dopamine infused into the rat nucleus accumbens.
    Barnes JC, Costall B, Domeney AM, Naylor RJ.
    Psychopharmacology (Berl); 1986 Apr 11; 89(3):311-6. PubMed ID: 3088656
    [Abstract] [Full Text] [Related]

  • 17. The effects on central dopamine function of chronic L-dopa (methyl ester hydrochloride) treatment of mice.
    Tabar J, Hashizume M, Cook CJ, Beart PM, Jackson DM.
    Pharmacol Biochem Behav; 1989 May 11; 33(1):139-46. PubMed ID: 2789405
    [Abstract] [Full Text] [Related]

  • 18. Receptor changes during chronic dopaminergic stimulation.
    Jenner P, Boyce S, Marsden CD.
    J Neural Transm Suppl; 1988 May 11; 27():161-75. PubMed ID: 2900291
    [Abstract] [Full Text] [Related]

  • 19. Central action of ketotifen.
    Rogóz Z, Skuza G, Sowińska H.
    Pol J Pharmacol Pharm; 1981 May 11; 33(5):503-15. PubMed ID: 7335554
    [Abstract] [Full Text] [Related]

  • 20. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
    Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Crotty K, Mueller RA.
    J Pharmacol Exp Ther; 1984 Nov 11; 231(2):343-54. PubMed ID: 6149306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.